## **Supplementary Data**

Intravenous Infusion of Phage-displayed Antibody Library in Human Cancer Patients: Enrichment and Cancer-Specificity of Tumor-Homing Phage-Antibodies

Girja S. Shukla\*, MS, PhD, David N. Krag, MD, FACS, Elena N. Peletskaya<sup>2</sup>, PhD, Stephanie C. Pero, PhD, Yu-Jing Sun, MD, PhD, Chelsea L. Carman, BA, Laurence E. McCahill<sup>2</sup>, MD, FACS, Thomas A. Roland<sup>1</sup>, MD

Department of Surgery and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA. <sup>1</sup>Radiation Oncology, Fletcher Allen Health Care, Burlington, VT 05401, USA.

<sup>2</sup><u>Present address</u>: ENP: Biolinx LLC, 20140 Scholar Dr., Ste 223, Hagerstown, MD 21742, USA; LEM: Richard J. Lacks Cancer Center, Saint Mary's Health Care, 250 Cherry Street SE, Grand Rapids, MI 49503,USA.

<u>\*Corresponding author:</u> Girja S. Shukla, Department of Surgery, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E309, Burlington, VT 05405, USA. Tel: 802-656-5830; Fax: 802-656-5833; Email: <u>Girja.Shukla@uvm.edu</u>

Task and parameters including blood analysis	Before infusion	Every 15 min during infusion	2 hrs after infusion	1-Week follow-up	1-Month follow-up	2-Month follow-up
Informed consent	X (Prior to any protocol event)					
Meeting with ombudsman	X					
Pre-medications	Х					
Physical examination	X			Х	Х	Х
Blood pressure	Х	Х	X		Х	Х
Pulse	X	Х	X		Х	Х
Temperature	X	X	X		Х	Х
Respiratory rate	X	Х	Х		Х	Х
Heart rate	X	Х	Х		Х	Х
Weight	X				Х	Х
Complete blood count	X				Х	Х
Creatinine	X				Х	Х
Albumin	X				Х	Х
Alkaline phosphatase	X				Х	Х
AST*	X				Х	Х
ALT**	X				Х	Х
Direct bilirubin	X				Х	Х
Total bilirubin	X				Х	Х
Total Protein	X				Х	Х
Anti-filamentous phage antibody	X					
Pregnancy testing as needed	X					
Pulmonary testing as needed	X					
Neurological testing as needed	X					
General level of consciousness	X	X	X	Х	Х	X
Toxicity monitoring for adverse events		X	X (All times throughout)	X	X	X

Supplementary Table S1: Schematic outline of the study and follow-up monitoring

\*AST=Aspartate aminotransferase, \*\*ALT=Alanine aminotransferase

## Supplementary Table S2:

Examples of matches by the tumor-binding scFv CDRH2 amino acid sequences to the variable regions of several interesting antibodies.

Clone number and Protein ID	Alignment of clones with human proteins	Name of aligning proteins	Comment
<b>09-8083</b> <b>08-0289</b> GB: ABD59021.1	1 SAI <mark>GAY</mark> G <b>NYTA</b> Y 12 1 SAISSTG <b>A</b> STTY 12 51 SGISSTGGATTY 62	Antibody to TREM- like transcript 1 (TLT1).	TLT1 is a costimulatory ITIM immunoreceptor in platelets similar to platelet endothelial cell adhesion molecule-1 and a mediator of metastasis [15].
<b>08-2081</b> <b>07-0299</b> GB: AAV66329.1	1 S <b>DIA</b> G <b>Y</b> GYTTSY 12 1 S <b>S</b> ING-G <b>N</b> TTSYA 12 49 S <b>G</b> INGTGYTTSYA 61	Human Ig C1 HC variable region to asialoglycoprotein receptor.	Asialoglycoprotein is involved in cell adhesion and cancer metastasis and used for hepatocellular carcinoma drug targeting [16].
<b>07-0365</b> GB: AAC26479.1	1 SSIA-TGYTTYYA 12 49 S <b>A</b> IS <mark>GS</mark> GYTTYYA 61	Human IgM HC to GM2 ganglioside.	The ganglioside antigens act as immunosuppressors of cytotoxic T cells and dendritic cells, promote tumor-associated angiogenesis, and regulate cell adhesion, motility and metastasis. They are directly connected with transducer molecules to initiate adhesion coupled with signaling, and are modulators of signal transduction through tyrosine kinases associated with growth factor receptors or other protein kinases [17].
<b>08-2035</b> GB: ACH41918.1	1 SGI <b>S</b> DDG <b>N</b> ST <b>A</b> Y <b>T</b> D 14 49 SGI <b>D</b> DDG <mark>G</mark> ST <b>N</b> Y <b>A</b> D 62	Single chain variable fragment to human VEGFR2.	Neovascularization in tumor tissue (unpublished).
<b>07-2355</b> PDB: 2VXS K	1 SAISGSGGSTYY 12 49 SAISGSGGSTYY 60	Human neutralizing antibody to IL-17A.	IL-17 induces MMP-9 expression via p38 MAPK and ERK1/2 dependent NF-kappaB and AP-1 activation [18]. Overexpressed in a variety of cancers [24,25].
<b>09-8033</b> GB: AAY15114.1	1 S <b>D</b> IGTSGYDTYY 12 49 S <b>A</b> IGTSG-DTYY 59	MOG-specific immunoglobulin heavy chain Fab fragment	(MOG) responsible for development of neurodegenerative disorders, such as MS and EAE [19].

The motifs are shown in grey highlighting. Exact matches of amino acids are shown in white; conservative substitutions are shown in black. GB = Gene bank ID; PDB = Protein data bank ID.

## **References:**

- 15. Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21 (1):38-46
- 16. Diez S, Navarro G, de ICT (2009) In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med 11 (1):38-45
- 17. Birkle S, Zeng G, Gao L, Yu RK, Aubry J (2003) Role of tumor-associated gangliosides in cancer progression. Biochimie 85 (3-4):455-463
- 18. Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Needham MR, Langham C, Barker W, Aziz A, Snow MJ, Dawson S, Welsh F, Wilkinson T, Vaugan T, Beste G, Bishop S, Popovic B, Rees G, Sleeman M, Tuske SJ, Coales SJ, Hamuro Y, Russell C (2009) Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol 394 (5):905-921. doi:S0022-2836(09)01236-4 [pii]
- 19. von Budingen HC, Menge T, Hauser SL, Genain CP (2006) Restrictive and diversifying elements of the anti-myelin/oligodendrocyte glycoprotein antibody response in primate experimental allergic encephalomyelitis. Immunogenetics 58 (2-3):122-128. doi:10.1007/s00251-006-0100-y
- 24. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206 (7):1457-1464. doi:jem.20090207 [pii]
- 25. Quan Y, Zhou B, Wang Y, Duan R, Wang K, Gao Q, Shi S, Song Y, Zhang L, Xi M (2012) Association between IL17 Polymorphisms and Risk of Cervical Cancer in Chinese Women. Clin Dev Immunol 2012:258293. doi:10.1155/2012/258293



Supplementary Figure 1: The results of immunofluorescence microscopy for tumor-binding were confirmed by tissue lysate ELISA. The tumor-specific phage-antibodies from patient 180-15 that showed binding to one normal human organ tissue were analyzed for their binding to 180-15 tumor and normal human skin lysates. The tumor-specific clones from patient 180-13 that showed binding to a maximum of two normal human organ tissues were analyzed for their binding to 180-13 tumor and normal human colon lysates. The bars represent the arithmetic mean $\pm$  SE (n=3) of the experiment done in triplicate. For all the clones, the tumor lysate bindings were significantly (p<0.001; Student t-test) higher in comparison to corresponding control normal tissue lysate.